Enlivex Therapeutics (ENLV) announced that the Company’s Board of Directors approved the purchase of up to $1 million of Bitcoin as part of its cash management strategy. “As demand for Bitcoin has grown, together with its rising acceptance as a recognized medium of exchange, we believe that Bitcoin will serve the Company as a strong and diversifying treasury reserve asset,” said Oren Hershkovitz, CEO of Enlivex. “With the recent approvals of Bitcoin ETFs and growing support from institutional investors, we believe that Bitcoin can provide the Company with a potential functional store of value and an inflation hedge to standard currencies.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex Initiates Promising Trial for Psoriatic Arthritis
- Enlivex completes dosing, follow-up for first patient in study of Allocetra
- Enlivex Advances Allocetra Trial for Knee Osteoarthritis
- Enlivex announces enrollment, dosing of first 10 patients in Allocetra trial
- Enlivex Therapeutics Reschedules Annual Shareholders Meeting